---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-102833"
form_type: "8-K"
ticker: "CTXR"
cik: "0001506251"
company_name: "Citius Pharmaceuticals, Inc."
filed_at: "2024-11-26T23:59:59+00:00"
generated_at: "2026-05-29T17:47:27.490237+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Citius Pharmaceuticals effects 1-for-25 reverse stock split to regain Nasdaq bid price compliance

## Summary
- Reverse split at 1-for-25 ratio effective Nov 25, 2024; split-adjusted trading begins Nov 26.
- Authorized shares reduced from 400M to 16M; issued shares from ~193M to ~7.7M.
- No fractional shares issued; fractional interests rounded up to nearest whole share.
- Intended to regain compliance with Nasdaq minimum $1.00 bid price requirement.
- Trading symbol remains CTXR; new CUSIP 17322U306.

## SEC filing metadata
- accession: 0001213900-24-102833
- form_type: 8-K
- ticker: CTXR
- cik: 0001506251
- company_name: Citius Pharmaceuticals, Inc.
- filed_at: 2024-11-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 3.03, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506251/000121390024102833/0001213900-24-102833-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506251/000121390024102833/ea0222380-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-102833
- JSON: https://secwatch.observer/filing/0001213900-24-102833.json
- Plain text: https://secwatch.observer/filing/0001213900-24-102833.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.